From my perspective, over the short-term (3 - 6 months), I don't...

From my perspective, over the short-term (3 - 6 months), I don't see the share price going over 70 cents given the poor macro picture with veritable market fragility. Until release of phase 3 results (Q1 CY2025), the share price will likely be constrained unless: a) market awareness of IXC significantly improves or b) new conditions are identified and pursued that materially increases TAM or c) phase 3 trial is completed earlier than expected (which is a possibility given the strong community demand for a therapeutic - meaning easily identifiable pool of patients) or d) a significant investor seeks to enter the share registry.

I'm happy to play the waiting game and of course grateful that financially I can afford to do so